Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Comparison of MwPharm 3.30 and MwPharm ++ a Windows version of pharmacokinetic software for PK/PD monitoring of vancomycin: a-priori modelling

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F22%3AA2302CXE" target="_blank" >RIV/61988987:17110/22:A2302CXE - isvavai.cz</a>

  • Výsledek na webu

    <a href="https://www.dustri.com/article_response_page.html?artId=189417&doi=10.5414/CP204151&L=0" target="_blank" >https://www.dustri.com/article_response_page.html?artId=189417&doi=10.5414/CP204151&L=0</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.5414/CP204151" target="_blank" >10.5414/CP204151</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Comparison of MwPharm 3.30 and MwPharm ++ a Windows version of pharmacokinetic software for PK/PD monitoring of vancomycin: a-priori modelling

  • Popis výsledku v původním jazyce

    Objective: To evaluate the possibility of population based dose optimisation with the aid of MWPharm modelling and to find the best model in the Windows version (WIN). Matherials: 25 patients repeatedly examined for vancomycin (mean age 63±14 years, body weight 88±21kg, median dose 1g/12 h). Methods: Trough concentrations predicted by WIN models “vancomycin_adult_k_C2“, ”#vancomycin_adult_C2“, ”vancomycin_adult_C2“, and ”vancomycin adult“ DOS model (DOS) were compared with the measured value. Statistics: The percentage prediction error (%PE) calculated as (predicted–measured)/measured values, Blandt-Altman plot, RMSE, Pearson’s coefficient of rank correlation (R). Data presented as mean ± SD. Student’s t-test were used for prediction precision evaluation. Results: The %PE varied from +44.4 ± 65.2% to +76.5 ± 84.3 %, P<0.001. ”#vancomycin_adult_C2“ model produced lowest %PE among WIN models as well as the lowest RMSE (79) and Blandt-Altman bias (-4.01 ± 7.59), but the Pearson’s correlation (0.6843, P=0.0002) was less tight. DOS model produced the second lowest RMSE (81), %PE (+45.9 ± 66.6%), and Blandt-Altman bias (-4.83 ± 6.97) and highest Pearson’s R (0.7847, P<0.0001). ”vancomycin_adult_C2“ produced the third best prediction: RMSE (113), %PE (62.8 ± 92.6%), Blandt-Altman bias (-6.78 ± 11.2) but Pearson’s R was the poorest (0.5773, P=0.0025). Conclusion: The lowest %PE and highest Pearson’s R were achieved by the ”#vancomycin_adult_C2“ model. Due to the poor predictive performance of all MWPharm versions and models we find all of them unsuitable for a-priori vancomycin dosing management. Other software should be evaluated for routine use.

  • Název v anglickém jazyce

    Comparison of MwPharm 3.30 and MwPharm ++ a Windows version of pharmacokinetic software for PK/PD monitoring of vancomycin: a-priori modelling

  • Popis výsledku anglicky

    Objective: To evaluate the possibility of population based dose optimisation with the aid of MWPharm modelling and to find the best model in the Windows version (WIN). Matherials: 25 patients repeatedly examined for vancomycin (mean age 63±14 years, body weight 88±21kg, median dose 1g/12 h). Methods: Trough concentrations predicted by WIN models “vancomycin_adult_k_C2“, ”#vancomycin_adult_C2“, ”vancomycin_adult_C2“, and ”vancomycin adult“ DOS model (DOS) were compared with the measured value. Statistics: The percentage prediction error (%PE) calculated as (predicted–measured)/measured values, Blandt-Altman plot, RMSE, Pearson’s coefficient of rank correlation (R). Data presented as mean ± SD. Student’s t-test were used for prediction precision evaluation. Results: The %PE varied from +44.4 ± 65.2% to +76.5 ± 84.3 %, P<0.001. ”#vancomycin_adult_C2“ model produced lowest %PE among WIN models as well as the lowest RMSE (79) and Blandt-Altman bias (-4.01 ± 7.59), but the Pearson’s correlation (0.6843, P=0.0002) was less tight. DOS model produced the second lowest RMSE (81), %PE (+45.9 ± 66.6%), and Blandt-Altman bias (-4.83 ± 6.97) and highest Pearson’s R (0.7847, P<0.0001). ”vancomycin_adult_C2“ produced the third best prediction: RMSE (113), %PE (62.8 ± 92.6%), Blandt-Altman bias (-6.78 ± 11.2) but Pearson’s R was the poorest (0.5773, P=0.0025). Conclusion: The lowest %PE and highest Pearson’s R were achieved by the ”#vancomycin_adult_C2“ model. Due to the poor predictive performance of all MWPharm versions and models we find all of them unsuitable for a-priori vancomycin dosing management. Other software should be evaluated for routine use.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30104 - Pharmacology and pharmacy

Návaznosti výsledku

  • Projekt

  • Návaznosti

    S - Specificky vyzkum na vysokych skolach

Ostatní

  • Rok uplatnění

    2022

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    International Journal of Clinical Pharmacology and Therapeutics

  • ISSN

    0946-1965

  • e-ISSN

  • Svazek periodika

  • Číslo periodika v rámci svazku

    7

  • Stát vydavatele periodika

    DE - Spolková republika Německo

  • Počet stran výsledku

    7

  • Strana od-do

    299-305

  • Kód UT WoS článku

    000817739500002

  • EID výsledku v databázi Scopus

    2-s2.0-85133102646